M. Lin

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

Ira M. Jacobson, Stuart C. Gordon, Kris V. Kowdley et al. · New England Journal of Medicine · 2013 · 1.1K citations · Full text

Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection

Graham R. Foster, Stephen Pianko, Ashley Brown et al. · Gastroenterology · 2015 · 249 citations · Full text

Hepatology, Hepatitis C, Viral Hepatitis +8

Barriers to hepatitis C treatment in the era of direct‐acting anti‐viral agents

M. Lin, Jennifer R. Kramer, Donna L. White et al. · Alimentary Pharmacology & Therapeutics · 2017 · 70 citations · Full text

LO5 : Sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: The boson study

Graham R. Foster, Stephen Pianko, Curtis Cooper et al. · Journal of Hepatology · 2015 · 43 citations

Boson Study, Genotype 3, Viral Persistence +12

6 ALL ORAL THERAPY WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 16 WEEKS IN TREATMENT EXPERIENCED GT2/3 HCV-INFECTED PATIENTS: RESULTS OF THE PHASE 3 FUSION TRIAL

David R. Nelson, J. Feld, K.V. Kowdley et al. · Journal of Hepatology · 2013 · 10 citations

Or 16, Viral Persistence, Hepatology +10